Some people are discovering that being thinner can sometimes mean looking older. Local cosmetic surgeons weigh-in with ...

West Pharmaceutical targets steady Q2 growth as high-value GLP-1 and SmartDose demand drives segment momentum.

More than one-third of people who helped develop the 2023 guidelines for treating children with obesity had undisclosed ...

In today's Morning Rounds newsletter: a failed long Covid drug may get another shot, the benefits of even a little activity ...

The investment is highlighted by a state-of-the-art API facility in Virginia and expansions across multiple states.

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Patients with idiopathic intracranial hypertension who use a GLP-1 receptor agonist are less likely to experience symptoms, require medications, or undergo surgery.

More than 1% of U.S. children between the ages of 2 and 18 had “extremely severe obesity” in 2023 — a 250% increase from 2008 ...

Discover how food brands can adapt to the rising GLP-1 trend. As weight-loss drugs reshape consumer habits, learn which ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

The biopharmaceutical company said the investment includes plans for a new manufacturing center focused on chronic diseases.

Commerce Secretary Howard Lutnick said Trump's new tariff policies are focused on ending the U.S.'s reliance on foreign supply of key pharmaceutical products. "We are proud that AstraZeneca has made ...